BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

Core Insights - BeOne Medicines Ltd. has received Breakthrough Therapy Designation from the FDA for sonrotoclax, a next-generation BCL2 inhibitor aimed at treating adult patients with relapsed or refractory mantle cell lymphoma [1] Company Summary - BeOne Medicines Ltd. is a global oncology company focused on developing innovative treatments for cancer [1] - The FDA's acceptance of BeOne's request indicates a significant step forward in the development of sonrotoclax for a challenging patient population [1]